Ameloblastoma is a benign odontogenic tumor of epithelial origin. It is locally aggressive with unlimited growth capacity and has a high potential for malignant transformation as well as metastasis. Ameloblastoma has no established preventive measures although majority of patients are between ages 30 and 60 years. Molecular and genetic factors that promote oncogenic transformation of odontogenic epithelium to ameloblastoma are strongly linked to dysregulation of multiple genes associated with mitogen-activated protein kinase, sonic hedgehog, and WNT/β-catenin signaling pathways.

Treatment of ameloblastoma is focused on surgical resection with a wide margin of normal tissue because of its high propensity for locoregional invasion; but this is often associated with significant patient morbidity. The relatively high recurrence rate of ameloblastoma is influenced by the type of molecular etiological factors, the management approach, and how early the patient presents for treatment. It is expected that further elucidation of molecular factors that orchestrate pathogenesis and recurrence of ameloblastoma will lead to new diagnostic markers and targeted drug therapies for ameloblastoma.
trauma, inflammation, nutritional deficiencies, non-specific irritation from extractions, and dental caries (Brown and Betz, 2015). As development of odontogenic tumors was associated with remnants of the migrating epithelium at the cervical loop of the enamel organ, it was not surprising that development of ameloblastoma was also linked to the enamel organ, remnants of odontogenic epithelium, and lining of odontogenic cyst (Sciubba et al., 2005). This odontogenic etiological origin was further supported by the similarities in the expression profiles of cytokeratin and vimentin between the developing tooth germ and ameloblastoma (Brown and Betz, 2015). Another earlier theory was associated with morphodifferentiation of pre-ameloblasts to ameloblasts during the bell stage of tooth development. It was believed that affected pre-ameloblasts propagate in the bell stage during tooth development instead of functionally inducing enamel protein synthesis and matrix deposition (Fan et al., 2012). Other studies have proposed that the absence of stratum intermedium hinders the differentiation of pre-ameloblasts to ameloblasts because the stratum intermedium produces alkaline phosphatase needed to breakdown nutritional elements that will be passed on to ameloblasts during the bell stage. This theory has been strengthened by the impaired ameloblast function and enamel deposition observed in Mxe-2 null mice that lacked functional stratum intermedium cells (Jussila and Thesleff, 2012). It should also be taken into account that the stellate reticulum within the tumor nests of columnar epithelium can degenerate to form microscopic cysts. The coalescing of these microcysts to form larger cystic spaces gives the multicystic features of ameloblastoma (Gupta et al., 2011).

At the molecular level, the genetic factors involved in tooth development, morphogenesis, cytodifferentiation, and tooth patterning have been associated with development of ameloblastoma because some of these are altered significantly in ameloblastic tissues. An analysis of 34 different genes demonstrated 11 overexpressed and 23 under-expressed genes relative to normal (Heikinheimo et al., 2002). Some of the overexpressed genes include c-fos proto-oncogene (FOS), tumor necrosis factor receptor 1A (TNFRSF1A), collagen type VIII alpha 1 (COL8A1), cyclin-dependent kinase inhibitor 1A (CDKN1A), matrix metalloproteinase 12 (macrophage elastase) (MMP-12), and matrix metalloproteinase 13 (collagenease 3) (MMP-13). The genes highly underexpressed included sonic hedgehog (SHH), TNF receptor-associated factor 3 (TRAF3), deleted in colorectal carcinoma, Rho GTPase-activating protein 4 (ARHGAP4), cadherin 12 (CDH12), cadherin 13 (CDH13), teratocarcinoma-derived growth factor 1 (TDGF1), transforming growth factor beta 1 (TGFβ1), patch (PTCH), and bone morphogenetic protein 2 (BMP2; Heikinheimo et al., 2002). More recent studies have also identified overexpression of WNT5A (wingless-type MMTV integration site family, member 5A) and WNT-1 that suggests they might be associated with the development of ameloblastoma (Sukarawan et al., 2010; Siar et al., 2012b). These earlier genetic studies were performed using microarrays, but more recently, some of these candidate genes have been sequenced to identify the mutations and variants associated with ameloblastoma (Heikinheimo et al., 2002). The molecular pathogenesis of ameloblastoma is now attributed to dysregulation of the mitogen-activated protein kinase (MAPK) pathway based on studies using ameloblastoma tissues, cell lines, and transgenic mice (Brown and Betz, 2015). BRAF, a serine/threonine protein kinase activating the MAPK/ERK signaling pathway strongly associated with melanoma, has also been implicated in over 63% of ameloblastoma (Brown et al., 2014; Kurppa et al., 2014; Sweeney et al., 2014). Interestingly, over 90% of BRAF mutations involve a substitution of valine for glutamate at codon 600 (V600E; Kurppa et al., 2014; Brown et al., 2015; Fregnani et al., 2017). The mutation causes constitutive activation of BRAF protein downstream of MEK/ERK that ultimately results in neoplastic transformation (Niall and Baccarini, 2010). To further strengthen the association of MAPK signaling with ameloblastoma, the mutations in the RAS gene that acts upstream of BRAF and fibroblast growth factor receptor 2 (FGFR2), a membrane-bound activator of MAPK signaling, have also been identified in ameloblastomas (Brown et al., 2014; Sweeney et al., 2014). Additionally, mutations in non-MAPK signaling genes especially smoothened (SMO), a G protein-coupled receptor and signaling effector component of the SHH signaling pathway, have also been described in ameloblastoma (Mishra et al., 2015). Taken together, these more recent molecular data strongly indicate the existence of unique genetic abnormalities that eventually lead to development of ameloblastoma (Sweeney et al., 2014; Brown and Betz, 2015; Brown et al., 2015).

**Advances in histopathogenesis of ameloblastoma**

As our understanding of odontogenic tumors including ameloblastoma increases, the classification of

---

**Figure 1** Maxillary Ameloblastoma. Extensive maxillary ameloblastoma in an African male patient. Note the extensive ameloblastoma-induced facial disfigurement and teeth displacement due to delayed access to treatment (Picture courtesy of Professor G. T Arotiba, Faculty of Dental Sciences, University of Lagos, Lagos Nigeria)
Current concepts in ameloblastoma
OA Effiom et al

Ameloblastoma will continue to evolve (Wright et al., 2014). According to an established World Health Organization (WHO) report on odontogenic tumors, ameloblastoma was classified into benign and malignant types based on its biologic behavior (Sciubba et al., 2005). Based on this report, each type was further subdivided into four subtypes based on anatomic location and histopathology. In order of frequency, the benign ameloblastomas include (i) solid/multicystic ameloblastoma, (ii) unicystic ameloblastoma, (iii) peripheral (or extraosseous) ameloblastoma, and (iv) desmoplastic ameloblastoma. Similarly, malignant ameloblastomas based on order of frequency include (i) metastasizing ameloblastoma, (ii) primary ameloblastic carcinoma, (iii) secondary intraosseous ameloblastic carcinoma, and (iv) secondary peripheral ameloblastic carcinoma (Table 1; Reichart et al., 1995; Sciubba et al., 2005). While the WHO classification provided a good guidance for management, it lacks precise terminology which limits its diagnostic application and international acceptance (Wright et al., 2014). A more contemporary classification of odontogenic tumors including ameloblastoma was proposed recently (Wright et al., 2014). The recommendations indicate that there is an authentic and existing concept of unicystic ameloblastoma, and most conventional ameloblastomas microscopically and macroscopically present with cystic degeneration. Therefore, the term ‘multicystic’ adds no worth but misperception to the designation ‘solid/multicystic ameloblastoma’. Hence, conventional lesions should simply be called ‘conventional ameloblastoma’ and the term ‘solid/multicystic’ be discarded. Additionally, the predominance of plexiform ameloblastoma in the posterior maxilla is not a reason for separating it as a different entity because it is still the distinctive site of occurrence for conventional ameloblastoma, so it should be considered as a histological type of conventional ameloblastoma. It was also proposed that the unique radiographic features of desmoplastic ameloblastoma, distinct from other histological types/subtypes, are a function of the desmoplasia. So, desmoplastic ameloblastoma should be simply noted for its distinctive radiographic and clinical presentation and considered a histological type like plexiform ameloblastoma rather than being considered as a separate entity (Wright et al., 2014). The proposed recommendations also stated that unicystic ameloblastoma is comprised of luminal and mural histopathological variants. Luminal unicystic ameloblastoma presents as a cystic

### Table 1 Clinicohistological types of ameloblastoma. Clinical, histologic, and radiographic features of the histological subtypes of ameloblastoma

<table>
<thead>
<tr>
<th>Types of ameloblastoma</th>
<th>Synonyms</th>
<th>Salient features</th>
<th>Conventional radiographic features</th>
<th>Histopathological variants</th>
</tr>
</thead>
<tbody>
<tr>
<td>Benign Solid/multicystic</td>
<td>Conventional/Classical ameloblastoma</td>
<td>Mean age: 36 years Male &gt; female Slightly higher in mandible</td>
<td>Unilocular radiolucency Multilocular radiolucency Unerupted tooth Root resorption</td>
<td>Cystic, acanthomatous, granular, basaloïd, spindle, clear cell, hemangiomatos</td>
</tr>
<tr>
<td>Unicystic</td>
<td>Cystogenic ameloblastoma</td>
<td>Dentigerous type: Mean age: 16.5 years Male &gt; female Non-dentigerous type: Mean age: 35.2 years Female &gt; male Slightly higher in mandible (posteriorly)</td>
<td>Unilocular radiolucency Multilocular radiolucency Unerupted tooth Unilocular radiolucency Multilocular radiolucency</td>
<td>Luminal (plexiform unicystic, intraluminal), mural</td>
</tr>
<tr>
<td>Peripheral</td>
<td>Extrasosseous/soft tissue ameloblastoma</td>
<td>Mean age: 51 years Male &gt; female Slightly higher in mandible Exophytic Mean size 1.3 cm</td>
<td>Saucerization</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Desmoplastic</td>
<td>Ameloblastoma with pronounced desmoplasia</td>
<td>Mean age: 41.6 years Female = male Maxilla = mandible</td>
<td>Mixed radiolucent/radiopaque Root resorption</td>
<td>Hybrid Desmoplastic ± osteoplasia</td>
</tr>
<tr>
<td>Malignant Metastasizing</td>
<td>Malignant ameloblastoma</td>
<td>Mean age: 34.4 years Male &gt; female Slightly higher in mandible Distant sites: lungs and other areas</td>
<td>Same as solid/multicystic</td>
<td>Same as solid/multicystic</td>
</tr>
<tr>
<td>Primary ameloblastic carcinoma</td>
<td>Not applicable</td>
<td>Mean age: 53 years Male &gt; female Higher in mandible (posteriorly)</td>
<td>Ill-defined multilocular radiolucency Foci of calcification</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Secondary ameloblastic carcinoma (intraosseous)</td>
<td>Carcinoma ex intraosseous ameloblastoma</td>
<td>Rapid growth, 7th decade Male &gt; female Slightly higher in mandible</td>
<td>Ill-defined multilocular radiolucency Foci of calcification</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Secondary ameloblastic carcinoma (peripheral)</td>
<td>Carcinoma ex peripheral ameloblastoma</td>
<td>Male = female Alveolar bone resorption</td>
<td>Intraradicular radiolucency</td>
<td>Not applicable</td>
</tr>
</tbody>
</table>
Oral Diseases

Ameloblastoma is a benign odontogenic tumor that arises from the odontogenic epithelium. It is the second most common odontogenic tumor, accounting for about 4% of all odontogenic tumors (Table 1). The tumor can occur at any age, but it is most common in adults between the ages of 20 and 40 years. The tumor is more common in men than in women. The most common location of ameloblastoma is the mandible, followed by the maxilla.

The tumor is usually asymptomatic, but it can present as a slow-growing painless swelling. Ameloblastoma can also present as a rapidly growing painless swelling, and it can present as a painful swelling.

Histologically, ameloblastoma is typically characterized by the presence of ameloblastomatous epithelium, which is a columnar epithelium that resembles the epithelium of the tooth bud. The ameloblastomatous epithelium can be arranged in a variety of patterns, including follicular, plexiform, and multicystic patterns.

Desmoplastic ameloblastoma is a rare variant of ameloblastoma that is characterized by the presence of a desmoplastic stroma. This variant is more common in the mandible than the maxilla.

Peripheral ameloblastoma is the least common variant of ameloblastoma, accounting for just 1% of ameloblastoma cases (Odukoya and Effiom, 2008; Siar et al., 2012a). Mostly affected are middle-aged patients with an average age of 52 years. These lesions are more common in the mandible than the maxilla and are found on posterior gingiva or alveolar sulcus. Histologically, peripheral ameloblastoma consists of islands of ameloblastic epithelium with similar histological pattern as solid/multicystic/conventional ameloblastoma (Figure 4a).

Desmoplastic ameloblastoma presents as a slow-growing painless swelling, but radiologically, it displays a mixed radiolucent/radiopaque pattern and irregular borders. The histological feature of extensive stromal dysplasia is pathognomonic (Figure 4b). It consists of islands of odontogenic epithelium with variable shapes and sizes proliferating within a highly collagenous connective tissue. The thick collagen fibers tend to compress the odontogenic epithelial islands from the periphery, giving rise to the bizarre shapes and sizes. It is not uncommon for desmoplastic ameloblastoma to contain metaplastic bone formations.

Metastasizing or malignant ameloblastoma is a previously benign ameloblastoma that has metastasized to a distant site usually the lungs. It is diagnosed based on clinical features and the rationalization that both primary and metastatic lesions display similar histological features of solid/multicystic/conventional ameloblastoma. Ameloblastic carcinoma can develop de novo: This is the primary type. Alternatively, it can develop secondarily from an initially benign ameloblastoma that loses differentiation to become a carcinoma. Ameloblastic carcinomas grow more rapidly and aggressively and can present as painful swellings that perforate the cortical bone. Histologically, ameloblastic carcinoma combines the overall histological patterns of an ameloblastoma with cytological atypia consisting of abnormal mitotic activities, cellular and nuclear hyperchromatism, and focal necrosis (Sciubba et al., 2005) (Figure 5).

Ameloblastoma presents clinically as a slow-growing relatively painless tumor. Due to its locally aggressive growth characteristics, ameloblastoma can rapidly become

![Figure 2](image-url)  
*Figure 2* Solid/Multicystic/Conventional ameloblastoma. (a) Follicular ameloblastoma connective tissue (Ct) contains islands of odontogenic epithelium (black arrows) delineated by peripheral columnar cells that display reverse polarization. There are islands of cystic degeneration containing central loose stellate reticulum-like cells (**). (b) Plexiform ameloblastoma connective tissue contains long anastomosing cords of odontogenic epithelium (black arrowheads) delineated by peripheral columnar cells that display reverse polarization and central loose stellate reticulum-like cells.
a massive and expansile tumor causing tooth mobility, tooth displacement, and a grotesque facial appearance if the patient delays getting treatment (Figures 1 and 6). The constitutive activation of BRAFV600E associated with development of ameloblastoma has also been attributed to its progression (Kurppa et al., 2014). This mutation correlates with several clinicopathological features of ameloblastoma such as location within the jaw, age of patient at diagnosis, histology, and possibly prognosis. For example, BRAF mutations have been shown to occur more in the mandible and in younger patients (Brown and Betz, 2015), while BRAF wild-type ameloblastomas occurred more in the maxilla and displayed shorter recurrence-free survival (Brown et al., 2014).

**Figure 5** Ameloblastic carcinoma. (a) At low magnification, ameloblastic carcinoma contains odontogenic epithelial islands (black arrows) lined by peripheral ameloblast-like cells within the connective tissue stroma (Ct). The epithelial islands contain central stellate reticulum-like cells (*) that display acanthomatous changes (black arrowhead). (b) At higher magnification, the central stellate reticulum-like cells (*) surrounded by peripheral ameloblast-like cells display nuclear hyperchromatism, pleomorphism, and mitotic figures.
Normal bone remodeling is regulated by the interactions of receptor activator of nuclear factor kappa B (RANK) on osteoclast precursors with its osteoblast membrane-bound ligand (RANKL). Osteoblasts also secrete osteopro- tegerin (OPG), a soluble receptor that interacts with RANKL to control RANK–RANKL interactions (Stefanik et al., 2008). As RANK, RANKL, and OPG are expressed in different variants of ameloblastoma, dysregulated RANK-RANKL signaling and altered levels of OPG have been associated with lesional bone loss in ameloblastoma (de Matos et al., 2013). The caspase-mediated apoptotic system is also disparately regulated in different variants of ameloblastoma leading to aberrant survival of ameloblastic tissue. The strong immunoreactivity of pAKT and PI3K in some variants of ameloblastoma, especially the plexiform histological pattern, suggests that AKT/PI3K pathway may be promoting proliferation of ameloblastic cells (Jhamb and Kramer, 2014).

Matrix metalloproteinases (MMPs) are capable of degrading extracellular matrixes, and ameloblastomas express high levels of MMP-1, MMP-2, and MMP-9 (Ribeiro et al., 2009). The local aggressiveness of ameloblastomas correlates with activity of MMP-2 that can degrade type IV collagen abundant in the basement membrane. As MMP-2 level is regulated by the activating and inhibitory actions of MMP-14 and tissue inhibitor of matrix metalloproteinases-2 (TIMP-2), respectively, altered levels of the MMP-14/MMP-2/TIMP-2 complex especially in solid multicystic and recurrent ameloblastoma have been attributed to the invasive growth properties of ameloblastoma (Zhang et al., 2010; Floreșcu et al., 2012). Also, as MMP-2, MMP-9, and MMP-13 interact with WNT signaling pathway, the local invasiveness of ameloblastoma is further enhanced by WNT-mediated proliferative signals (Yamagata et al., 2012). In the same vein, podoplanin, a mucin-type transmembrane glycoprotein, has been shown to be much more strongly expressed in the peripherally located columnar cells than the central stellate reticulum-like cells of ameloblastomas. Hence, a differential expression pattern of podoplanin possibly contributes to the migration, aggregation, and recurrence of ameloblastoma cells (Siar et al., 2015).

Other molecular pathways that have been associated with the pathogenesis, invasiveness, and recurrence of ameloblastoma include but are not limited to p53-MDM2 (Kitkumthorn et al, 2010) and Notch signaling pathways (Siar et al, 2010) as well molecular markers such as syndecan-1 (CD138) (Al-Otaibi et al., 2013; Safadi et al, 2016) and CD10 (Abdel-Aziz and Amin, 2012). Some of these have also been considered as either diagnostic or prognostic markers of ameloblastoma (Jhamb and Kramer, 2014).
Current management approaches in ameloblastoma

Diagnostic imaging
The outcomes of a thorough clinical evaluation combined with different imaging modalities and histopathology are paramount to successful management of ameloblastoma irrespective of the histological subtype. Depending on how early the patient presents for evaluation, the clinical appearance of ameloblastoma may range from an innocuous intraoral swelling that the patient is unaware of to a grotesque orofacial swelling. Due to delayed access to health care in some developing countries in Africa and Asia, patients often present with a dramatically large ameloblastoma lesion (Figures 1 and 6). Different imaging modalities may have to be combined for evaluation, diagnosis, and treatment planning of ameloblastomas. These include plain film radiography, cone-beam computed tomography (CT), conventional CT, magnetic resonance imaging (MRI), and functional imaging that combines positron emission tomography (PET) with conventional CT (PET/CT; Fujita et al., 2013). The use of plain film radiography is a good starting point. While it displays to some extent the multilocular pattern of ameloblastoma, it cannot demonstrate the three-dimensional structural expanse of ameloblastoma. Conventional CT with or without contrast is the gold standard for evaluation of both primary and recurrent ameloblastomas. It accurately defines the radiodensity as well as multilocular and marginal details of ameloblastoma, which are vital for treatment planning (Figure 7). The use of MRI provides valuable details of the bone marrow and soft tissue components within and beyond the lesional margins of ameloblastomas. This is especially useful in delineating the extensions of maxillary ameloblastomas within the maxillary sinuses, orbits, and skull (Fujita et al., 2013). Functional imaging combining PET/CT is particularly useful for diagnosing malignant ameloblastoma as well as its extensive soft tissue infiltration and distant metastasis. As imaging studies do not provide definitive diagnosis of an ameloblastoma, it is imperative to biopsy the lesion for histopathological analysis and subtyping.

Surgical approaches
Both primary and recurrent ameloblastomas are treated by either surgical or non-surgical approach. The surgical approach could be conservative (type I) or radical (type II) surgery (Figure 6). The conservative surgical treatment could be in the form of enucleation and cautereutage, curettage, cryotherapy, or marsupialization. Conservative surgery preserves the patient’s normal tissues, minimizes facial disfigurement, and supports adequate quality of life postsurgery; but it is prone to higher recurrence especially if the ameloblastoma is the aggressive subtype (Dandriyal et al., 2011). Radical surgical treatment is customarily the treatment of choice for biologically aggressive subtype of primary and recurrent ameloblastomas. It involves en bloc tumor resection with wide bone margin followed by immediate or delayed bone reconstruction of the surgical defect with tissue grafts and prosthetic rehabilitation (Shen et al., 2015). The interrelationship between clinical and histological properties of the ameloblastoma determines its aggressiveness which in turn dictates the treatment approach and recurrence. However, treatment is also affected by the patient’s physical and medical conditions, the patient’s wishes regarding potential facial deformity,
compliance, and the psychological effect on quality of life postsurgery. The impact of surgery on facial growth and development in pediatric patients should also be considered during treatment planning. Surgical treatment in pediatric ameloblastoma patients is still controversial. Advocates for conservative surgery favor maintaining a good quality of life post-treatment over recurrence for a pediatric ameloblastoma patient (Huang et al., 2007). Others, however, support radical surgery for cases with multiple recurrences, in poorly compliant pediatric patients and in environments where follow-up procedures are limited (Odukoya and Effiom, 2008; Bassey et al., 2014). However, if recurrence is the major consideration, surgeons are encouraged to select aggressive radical surgery irrespective of the patient’s age except in patients with poor health due to other underlying medical conditions. Conservative surgical excision with peripheral ostectomy is the usual treatment approach for primary or recurrent peripheral ameloblastomas because it presents as a peripheral soft tissue lesion. Interestingly, rate of recurrence of peripheral ameloblastomas after conservative surgery is very low (Hertog et al., 2011).

Non-surgical approaches
Different forms of radiation therapy have been used successfully for non-surgical management of ameloblastomas especially in patients medically unstable for surgery (Kennedy et al., 2016). These include helical tomotherapy, image guided radiation therapy, intensity-modulated radiation therapy, and proton beam therapy. Some of these treatment modalities have been combined with surgery and/or chemotherapy. The therapeutic use of adjuvant radiotherapy with or without chemotherapy for positive margins of recurrent and unresectable ameloblastomas has resulted in mixed outcomes. However, their use is still strongly advocated to treat ameloblastic carcinoma and recurrent ameloblastoma after multiple postsurgical recurrences (Huang et al., 2014). During treatment planning, it is imperative to balance the efficacy of radiotherapy with risks of developing future life-threatening malignant transformations.

The efficacy of chemotherapy in the management of primary and recurrent ameloblastomas is still being explored as chemotherapy can improve clinical outcomes in non-surgical patients. Several drug regimens may be used in combination with surgical resection and/or radiotherapy. These include the combinations of vinblastine + cisplatin + bleomycin; Adriamycin + cisplatin + cyclophosphamide; doxorubicin + cisplatin; and gemcitabine + carboplatin (Van Dam et al., 2010; Amzerin et al., 2011). However, there is still a need for more multicenter randomized controlled clinical studies to validate the use of radiation and chemotherapy as treatment options for ameloblastoma. Interestingly, bone loss in ameloblastoma associated with dysregulated RANK/ RANKL/OPG interactions (de Matos et al., 2013) has led to the suggestion that antiresorptives such as denosumab may be effective in controlling the local aggressiveness of ameloblastoma (Jhamb and Kramer, 2014). Unfortunately, a major side effect of antiresorptives is osteonecrosis of the jaw (Akintoye and Hersh, 2016; Omolehinwa and Akintoye, 2016), so the potential clinical benefits must be balanced with their established side effects to justify their use in ameloblastoma therapy.

Targeted directed therapies
Recent advances in the molecular signaling pathways associated with pathogenesis of ameloblastoma have led to development of targeted therapies for management of ameloblastoma (Sauk et al., 2010). Several MAPK-specific drugs selectively inhibit the functions of mutated BRAF and MEK to stop the dysregulated proliferation and differentiation of ameloblastic cells. These include vemurafenib and dabrafenib, which inhibit mutated BRAF gene; trametinib, an inhibitor of mutated MEK gene; and ponatinib and regorafenib that inhibit mutated FGFR2 genes. Regrettably, resistance mechanisms such as compensatory activation of the MAPK kinase pathway by epidermal growth factor receptor have been associated with vemurafenib treatment for ameloblastoma (Kurppa et al., 2014; Heikinheimo et al., 2015). This had led to the suggestion that mutated MEK inhibitors may be desirable than mutant BRAF inhibitors for treating ameloblastoma (Heikinheimo et al., 2015).

Similarly, targeted therapies have been developed to control the effect of SMO mutation associated with pathogenesis of ameloblastoma (Mishra et al., 2015). These include vismodegib and irtraconazole, which unfortunately have been less successful in controlling ameloblastoma associated with SMO mutations W535L and L412F due to resistance mechanisms that block binding of SMO-targeted drugs (Sweeney et al., 2014). On the contrary, arsenic trioxide and KAAD-cyclopamine are known to be highly effective against these same mutations and may be useful in the treatment of ameloblastoma associated with SHH signaling pathway (Sweeney et al., 2014). As SHH expression is high in ameloblastomas, several drugs already developed to antagonize SHH signaling offer other non-surgical targeted therapeutic options for ameloblastoma patients (Mishra et al., 2015). Among these, cyclopamine is the most widely used, but its main drawback is the inhibition of osteoblastic proliferation and differentiation that are important for bone healing (Stanton and Peng, 2010; Schaefer et al., 2013).

Recurrence of ameloblastoma
The relatively high post-treatment recurrence of ameloblastoma is a major challenge (Figure 6). This can be attributed to its local invasiveness, different histological variants with peculiar tissue components, the treatment approach, and how early the patient presents for treatment (Ribeiro et al., 2009; Zhang et al., 2010). The potential for tumor seeding at the surgical site is also attributed to high recurrence of ameloblastoma. Solid/multicystic/conventional ameloblastoma is associated with the highest rate of recurrence (Antonoglou and Sandor, 2015) especially if treated by conservative surgery. Similarly, the tendency to treat luminal unicystic ameloblastoma by conservative approach also leads to recurrence, but recurrence is much lower for unicystic than solid multicystic ameloblastoma and malignant ameloblastoma (Antonoglou and Sandor, 2015).
2015). Interestingly, SMO gene mutation appears to be associated with higher recurrence of ameloblastoma than other genetic mutations identified in ameloblastoma (Sweeney et al, 2014). This has led to the assertion that BRAF and other non-SMO genetic mutations might confer better prognosis (Brown et al, 2014). A conservative surgical approach to treat ameloblastic carcinoma also leads to high recurrence, so radical surgery is mostly advocated for treatment of ameloblastic carcinoma irrespective of its histological features. The recommended treatment approach for recurrent ameloblastoma is radical surgery which confers disease-free survival and the absence of secondary recurrence for at least 10 years (Hertog et al, 2011). There are promising results that higher expression levels of cancer stem cells as indicated by CD44 in ameloblastoma may be associated with tumor recurrence, but the sensitivity and specificity of CD44 as a test for ameloblastoma recurrence are yet to be fully clarified. (Sathi et al, 2012).

Taken together, successful management of primary and recurrent ameloblastomas involves balancing radical surgery that has a margin wide enough to prevent recurrences with another less tissue-destructive therapeutic option (Kennedy et al, 2016). The goals are to minimize morbidity and improve survivorship and the patient’s quality of life. Adequate periodic clinical and radiographic follow-up for at least 10 years is highly essential. There is optimism that ongoing research will eventually lead to newer therapies targeting both MAPK and non-MAPK signaling pathways.

Acknowledgements

This work was supported by United States Institute of International Education/the Council for International Exchange of Scholars (IIIE/CIES) Fulbright scholarship (awarded to Sunday O. Akintoye). The authors thank Professor G. T Arotiba (Faculty of Dental Sciences, University of Lagos, Lagos Nigeria) for the clinical pictures and Drs. Mel Muparappu and David M. Graham (School of Dental Medicine, University of Pennsylvania) for the radiology images.

Conflict of interest

The authors declare that they have no conflict of interest.

Author contributions

O.A. Effiom, O.M. Ogundana and A.O. Akinshiko participated in literature review and writing of the manuscript. S.O. Akintoye conceptualized the review project and participated in the literature review, writing and editing of the manuscript.

References


Current concepts in ameloblastoma

OA Effiom et al


